The Non-Hodgkin’s Lymphoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Non-Hodgkin’s Lymphoma (NHL): An Overview
Non-Hodgkin lymphoma is a type of cancer that generally develops in the lymph nodes and lymphatic tissue found in organs such as the stomach, intestines, or skin. In some cases, NHL involves bone marrow and blood. NHL is not just one disease–it’s actually a diverse group of blood cancers that all arise from lymphocytes (white blood cells that are part of the immune system). Lymphoma cells may develop in just one place or in many sites in the body. NHL has many different subtypes, which are either indolent (slow-growing) or aggressive (fast-growing).
Non-Hodgkin lymphoma is divided into more than 30 types, classified based on the type of lymphocyte involved: B lymphocytes (B cells) or T lymphocytes (T cells). Non-Hodgkin lymphoma is further classified by other factors, including whether it is aggressive (fast-growing) or indolent (slow-growing).
As per the American Cancer Society (2022), NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. About 80,400+ people are anticipated to be diagnosed with NHL in 2022.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Non-Hodgkin’s Lymphoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Non-Hodgkin’s Lymphoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Non-Hodgkin’s Lymphoma (NHL) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Non-Hodgkin’s Lymphoma Epidemiology, Segmented by –
Total Incident Cases of Non-Hodgkin’s Lymphoma
Type-specific Incident Cases of Non-Hodgkin’s Lymphoma
Stage-specific Incident Cases of Non-Hodgkin’s Lymphoma
Age-specific Incident Cases of Non-Hodgkin’s Lymphoma
Treatable Cases of Non-Hodgkin’s Lymphoma by Line of Therapies
Non-Hodgkin’s Lymphoma (NHL) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Hodgkin’s Lymphoma market or expected to be launched during the study period. The analysis covers the Non-Hodgkin’s Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Hodgkin’s Lymphoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Non-Hodgkin’s Lymphoma Market Will Evolve and Grow by 2032 @
Non-Hodgkin’s Lymphoma (NHL) Therapeutics Analysis
The treatment of Non-Hodgkin’s Lymphoma depends upon the severity and spread rate of the disease. Various types of treatment regimens are used to treat NHL, such as chemotherapy and other drug therapy, radiation therapy (usually combined with chemotherapy), stem cell transplantation, and watch-and-wait. If the patient does not respond to these, targeted therapies are used. To further improve the treatment scenario, globally, several key companies are actively working in the Non-Hodgkin’s Lymphoma Therapeutics Market.
The Leading Companies in the Non-Hodgkin’s Lymphoma Therapeutics Market Include:
Jiangsu Hengrui Medicine
Non-Hodgkin’s Lymphoma Therapies Covered in the Report Include:
ZN-d5: Zentera Therapeutics
PCLX-001: Pacylex Pharmaceuticals
LOXO-305: Loxo Oncology
AB-101: Artiva Biotherapeutics
AB-205: Angiocrine Bioscience
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Non-Hodgkin’s Lymphoma Competitive Intelligence Analysis
4. Non-Hodgkin’s Lymphoma Market Overview at a Glance
5. Non-Hodgkin’s Lymphoma Disease Background and Overview
6. Non-Hodgkin’s Lymphoma Patient Journey
7. Non-Hodgkin’s Lymphoma Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Non-Hodgkin’s Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Hodgkin’s Lymphoma Unmet Needs
10. Key Endpoints of Non-Hodgkin’s Lymphoma Treatment
11. Non-Hodgkin’s Lymphoma Marketed Products
12. Non-Hodgkin’s Lymphoma Emerging Drugs and Latest Therapeutic Advances
13. Non-Hodgkin’s Lymphoma Seven Major Market Analysis
14. Attribute Analysis
15. Non-Hodgkin’s Lymphoma Market Outlook (In US, EU5, and Japan)
16. Non-Hodgkin’s Lymphoma Access and Reimbursement Overview
17. KOL Views on the Non-Hodgkin’s Lymphoma Market
18. Non-Hodgkin’s Lymphoma Market Drivers
19. Non-Hodgkin’s Lymphoma Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
“Non-Hodgkin’s Lymphoma (NHL) Pipeline Insights, 2023” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin’s Lymphoma market. The report embraces in-depth commercial and clinical assessment of the Non-Hodgkin’s Lymphoma pipeline products from the pre-clinical developmental phase to the marketed phase.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States